These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33305635)

  • 1. Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?
    Shalini ; Kumar V
    Expert Opin Drug Discov; 2021 Apr; 16(4):335-363. PubMed ID: 33305635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
    Seo SY
    Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of molecular hybrids in drug discovery.
    Bérubé G
    Expert Opin Drug Discov; 2016; 11(3):281-305. PubMed ID: 26727036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
    Simões-Pires CA; Bertrand P; Cuendet M
    Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.
    Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G
    Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and potential clinical utility of biomarkers for HDAC inhibitors.
    Shi B; Xu W
    Drug Discov Ther; 2013 Aug; 7(4):129-36. PubMed ID: 24071574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the development of hybrid anticancer drugs.
    Fortin S; Bérubé G
    Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
    Peng FW; Wu TT; Ren ZW; Xue JY; Shi L
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
    Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
    Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
    Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
    Zang J; Liang X; Huang Y; Jia Y; Li X; Xu W; Chou CJ; Zhang Y
    J Med Chem; 2018 Jun; 61(12):5304-5322. PubMed ID: 29787262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
    Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
    J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
    Sangwan R; Rajan R; Mandal PK
    Eur J Med Chem; 2018 Oct; 158():620-706. PubMed ID: 30245394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
    Zhao C; Dong H; Xu Q; Zhang Y
    Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.